Germany’s Merck KGaA agreed Monday to acquire Nasdaq-listed Silence Therapeutics (SLN) for $1.3 billion in cash, offering a premium of more than 100% to Friday’s close, signaling renewed appetite for RNA-interference assets in a tightening biotech M&A market.1
The deal hands Merck KGaA a portfolio of investigational RNAi therapies targeting cardiovascular and haematology indications, potentially broadening its specialty-medicine pipeline at a time when large-cap pharma is under pressure to offset patent-cliff revenue losses.
Key Takeaways
- Merck KGaA bids $20 per ADS – more than double Friday’s close.
- All-cash deal values Silence Therapeutics at roughly $1.3 billion.
- Transaction extends RNAi consolidation trend across large-cap pharma.
Deal Terms & Immediate Market Reaction
Merck KGaA said it is offering $20 in cash for each American depositary share of Silence Therapeutics (SLN), representing a premium exceeding 100% to the London-founded biotech’s closing price as of Friday.1 The implied enterprise value of approximately $1.3 billion places the transaction among the larger single-asset RNAi acquisitions in recent memory, trailing only Alnylam Pharmaceuticals’ broader platform deals in scale.
SLN shares surged sharply on the news, consistent with the pattern seen across recent biotech takeouts where target stocks trade near or at the offer price on day one. By contrast, the broader NASDAQ Biotechnology Index has trended lower through most of 2026, making the premium particularly striking against a subdued sector backdrop.
Strategic Rationale: Why RNAi, Why Now
RNAi therapeutics have moved from experimental curiosity to validated modality over the past five years, with approved drugs from Alnylam and Arrowhead Pharmaceuticals demonstrating durable silencing of disease-causing genes. Silence Therapeutics has built a proprietary mRNAi GOLD platform designed to optimise delivery of small-interfering RNA to the liver, an organ implicated in a range of metabolic and cardiovascular disorders.
For Merck KGaA’s healthcare division, absorbing that platform offers a shortcut to a mechanism it does not currently own at scale. The move echoes a broader industry pattern: AstraZeneca’s $1 billion Massachusetts R&D expansion earlier this year similarly reflected a strategic push to deepen next-generation therapeutic capabilities rather than rely solely on in-house discovery.
Biotech Consolidation Context
The transaction arrives as deal velocity in biotech has rebounded from the 2023-2024 trough, with acquirers returning to bolt-on purchases of platform-stage companies that carry de-risked but not yet fully commercial assets. That dynamic has also touched the dealmaking environment elsewhere in the sector; discussions around potential cross-border transactions have at times been complicated by trade-policy uncertainty, as seen when the Gilead-Ouro biotech deal was paused amid a tariff standoff.
Silence Therapeutics fits the profile of a preferred target: a single-country regulatory footprint, a Nasdaq listing providing price transparency, and a lead asset – zerlasiran, an investigational RNAi therapy for elevated lipoprotein(a) – that addresses a large unmet cardiovascular need with no currently approved pharmacological treatment.
Outlook & Management Perspective
Merck KGaA said the acquisition is expected to strengthen its pipeline in cardiometabolic disease, a therapeutic area where competition from established players is intensifying. The German science and technology company has positioned healthcare alongside its life-science tools and electronics businesses as a core growth engine, and the Silence deal represents one of its most sizeable single healthcare transactions in recent years.
“This acquisition reflects our commitment to accessing innovative platforms that can deliver transformative medicines to patients with high unmet needs,” Merck KGaA said in deal documentation, according to the announcement.1
Closing is subject to customary regulatory approvals and a Silence Therapeutics shareholder vote; no timeline to completion was disclosed in Monday’s announcement.
Conclusion
At $20 per ADS and a headline value of $1.3 billion, Merck KGaA’s purchase of Silence Therapeutics ranks as a significant premium bet on RNAi as a durable therapeutic modality. For macro and sector investors monitoring biotech consolidation velocity, the deal reinforces that large-cap acquirers remain willing to pay up for validated delivery platforms – even as broader equity markets keep biotech valuations under pressure.
Not investment advice. For informational purposes only.
References
1(2026, October 19). “Germany’s Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion”. The Wall Street Journal. Retrieved October 19, 2026.